- Home
- VACI vs TOI Comparison
VACI vs TOI Comparison
Compare VACI & TOI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | VACI | TOI |
|---|---|---|
| Founded | 2025 | 2007 |
| Country | United States | United States |
| Employees | 3 | 641 |
| Industry | Telecommunications Equipment | Medical/Nursing Services |
| Sector | Telecommunications | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 318.3M | 304.4M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | VACI | TOI |
|---|---|---|
| Price | $10.30 | $4.87 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $6.67 |
| AVG Volume (30 Days) | 359.5K | ★ 1.8M |
| Earning Date | 01-01-0001 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $30.15 |
| Revenue Next Year | N/A | $25.77 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $9.86 | $2.02 |
| 52 Week High | $10.49 | $4.90 |
Technical Indicators
Market Signals| Indicator | VACI | TOI |
|---|---|---|
| Relative Strength Index (RSI) | 55.33 | 67.51 |
| Support Level | $9.88 | $3.10 |
| Resistance Level | $10.49 | N/A |
| Average True Range (ATR) | 0.09 | 0.32 |
| MACD | -0.01 | 0.01 |
| Stochastic Oscillator | 17.39 | 86.07 |
Price Performance
Historical ComparisonAbout VACI Viking Acquisition Corp. I Class A Ordinary Shares
Viking Acquisition Corp I is a blank check company.
About TOI The Oncology Institute Inc.
The Oncology Institute Inc offers oncology care and treatment services to patients through several clinics located across the United States. It offers services such as infusion chemotherapy, oral drug chemotherapy, hospice and palliative care, autologous stem cell transplants, outpatient blood product transfusions, patient navigator programs, radiation oncology, and others on a fee or value-based model. Additionally, the company enrolls patients in clinical trials, where appropriate. The company has three operating segments: Specialty Pharmacy, Patient Services, and Clinical Trials and Other. Maximum revenue is generated from the Specialty Pharmacy segment, which operates specialty and retail pharmacies providing IV-infused, oral, injectable, and other medications for oncology treatment.